SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentation… […]
PALO ALTO, Calif.–(BUSINESS WIRE)– #AACR21–Immune-Onc Therapeutics Announces First Public Presentation of Data for its Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21 […]
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #aacr21–Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood draw, today announced results of an analysi… […]
BURLINGAME, Calif.–(BUSINESS WIRE)–Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the first presentation of preclinical data demonstrating po… […]
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. What … […]
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors g… […]
John Robinson Biotech is a small world — and all the more so in a tight-knit community like Boulder, CO. A serendipitous reunion with Andrew Robbins, a former colleague at Array, was what sparked John Robinson’s jump to his new gig as CSO of Cogent Bio… […]
German small-cap Affimed has long been highlighted as a potential Cinderella story, winning milestone-rich deals with Genentech and Roivant. And on Friday the biotech continued its NK cell march, presenting the first look at in-human data ahead of this… […]
Most experts agree the industry is transitioning toward a virtual care model, going from medical clinics and hospitals straight into people’s living rooms, bedrooms and possibly even their toilets.
Eli Lilly has won three emergency use authorizations for Covid-19 treatments, two for its antibody cocktail containing bamlanivimab and one featuring its Incyte-parntered drug Olumiant, in combination with Gilead’s remdesivir. But the US stopped distri… […]
Copyright © 2021 | MH Magazine WordPress Theme by MH Themes
